MarketMoodz
Cramer: Moderna’s Pipeline Could Re-rate Its Stock
Jim Cramer told viewers that Moderna has evolved beyond its Covid-era business and that a growing oncology and vaccine pipeline could unlock long-term growth for the stock. He praised the Science Day roadmap but advised investors to wait for a pullback before buying.
Key Takeaways
- Cramer said Moderna has moved beyond a Covid-only business and is building long-term value through oncology and new vaccine programs.
- Moderna shares have surged about 150% year-to-date, making it one of the S&P 500’s top gainers not tied to AI infrastructure.
- The stock remains below its pandemic-era high of $484 from August 2021 despite roughly a 20% rally since Science Day.
- An FDA advisory committee recommended approval of Moderna’s experimental flu vaccine ahead of an Aug. 5 regulatory decision, and the European Commission approved a combo Covid/flu shot earlier this year.
- Cramer urged patience—he recommends waiting for a pullback before adding Moderna to a portfolio.
People Involved
- Jim CramerCNBC host and investor commentator
Entities Involved
- Moderna, Inc. (MRNA)Biotech company shifting from Covid vaccine revenue to a broader oncology and vaccine pipeline
- Merck & Co., Inc. (MRK)Partner via Keytruda, oncology collaborator for combination trials
- U.S. Food and Drug Administration advisory committeeRegulatory panel that reportedly recommended Moderna’s experimental flu vaccine ahead of an Aug. 5 decision
- European CommissionRegulator that approved Moderna’s combination Covid/flu vaccine earlier this year
MarketMoodz Analysis
For investors, Cramer’s take reframes Moderna as a pipeline-driven biotech rather than a single-product Covid play, which matters for valuation. A diversified set of mid- and late-stage oncology programs—melanoma, non-small-cell lung cancer, renal cell carcinoma and bladder cancer—plus new vaccine candidates give the company multiple binary catalysts. That’s one reason the stock has jumped roughly 150% this year and rallied about 20% since Moderna’s Science Day; market participants are pricing in the possibility of sustained growth beyond Covid vaccine revenue. Still, the shares sit well under the pandemic high of $484, so current gains already factor in a fair amount of optimism.
History shows biotech re-ratings hinge on clinical readouts and regulatory outcomes, not just rhetoric. The reported FDA advisory committee recommendation for Moderna’s experimental flu vaccine and the European Commission’s approval of a combo Covid/flu shot are important validation points, but they don’t guarantee commercial success or favorable pricing. The melanoma combo study with Merck’s Keytruda is a high-profile potential catalyst—if late-stage data due later this year is positive, it could materially change revenue expectations. Caveats: some program names in coverage (for example, a referenced 'Intismeran') need independent verification against company filings and trial registries, and investors should watch actual trial readouts, FDA decisions (notably the Aug. 5 date), and uptake/pricing dynamics before assuming a durable rerating.
Source: Original Article